Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP deliveryMatthew R. Wilson, Pam McKay, Matthew A. Timmins et al.|Blood Advances|2020Cited by 54
Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCLMichael Northend, William Townsend, William Wilson et al.|Blood Advances|2022Cited by 44
Latest Results From an Ongoing First-in-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell MalignanciesKim Linton, Alexey V. Danilov, Graham P. Collins et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 5
CLL-638 Latest Results From an Ongoing Firstin-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell MalignanciesKim Linton, Alexey V. Danilov, Graham P. Collins et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 2
IBCL-675: Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Shows High Clinical Activity and Tolerable Safety in an Ongoing Phase 1a/b Study in Patients With Waldenström Macroglobulinemia (WM)Dima El‐Sharkawi, Nirav N. Shah, David Lewis et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 1